Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Eltrombopag combined with immunosuppressive therapy shows promising efficacy in severe aplastic anemia, especially in relapsed/refractory pediatric patients, with over half achieving hematologic responses and transfusion independence, suppo
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
Hetrombopag demonstrates comparable efficacy and safety to thrombopoietin for platelet engraftment after allogeneic hematopoietic stem cell transplantation, offering a promising alternative in hematologic care.
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.
Subcutaneous blinatumomab demonstrates promising efficacy and manageable safety in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with potential to shift future administration paradigms.
Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.
The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.
The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therap
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Open language-specific specialty feeds and department pages.